Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia

Abstract

Introduction: Majority of the Colombian population has become health insured leading to improved healthcare access in the country. Health care expenses have risen drastically, and cancer is responsible for the major disease burden. An option to reduce cost burden is to replace the use of originator drug products with generic formulations which are considered to be bioequivalent to the originator drugs and cost much less. We conducted a cost-minimization study for Colombia to assess the savings that could be achieved with the use of generic formulations of three anticancer drugs, namely bortezomib, decitabine and capecitabine as compared to their originator products. Methods: We compared the prices of originator and Dr Reddy's Laboratories Ltd generic equivalents of bortezomib, decitabine and capecitabine in Colombia for the year 2015. Prices of originator drugs were obtained from SISMED (Sistema de información de Precios de Medicamentos - Drug Price Information System), the prices of generic drugs were provided by Dr Reddy's Laboratories Ltd. Cost savings were estimated in value and percentages. Results: The study showed the substantial savings of 63% (US$4.68 million) with bortezomib, 26% (US$0.29 million) with decitabine, and 46% (US$1.50 million) with capecitabine from Dr Reddy's Laboratories Ltd generics as compared to their originator branded medicines. Conclusion: Considering the high economic burden of cancer and high prices of originator anticancer drugs, our study highlights the need to replace the originator branded medicines with the generics. This will not only improve the patient access to medications but also be beneficial for the insurance payers in Colombia, thereby improving the overall healthcare system in the country.